• Takeda to sell assets in Asia Pacific to Celltrion for $266m pharmaceutical-technology
    June 15, 2020
    Takeda Pharmaceutical has signed an agreement to sell certain non-core over-the-counter (OTC) and prescription pharmaceutical assets available only in the Asia Pacific to South Korean biopharmaceutical firm Celltrion for $266m in an upfront payment.
PharmaSources Customer Service